{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:32:32Z","timestamp":1775561552229,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.coph.2016.01.007","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:32:38Z","timestamp":1456965158000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cardiovascular risk reduction: the future of cholesterol lowering drugs"],"prefix":"10.1016","volume":"27","author":[{"given":"Sarah","family":"Bou Malham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Carol","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2016.01.007_sbref0005","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.007_bib0010","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1161\/01.cir.0000437740.48606.d1","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Eckel","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.01.007_bib0015","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta analysis of data from 170000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.007_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0163-7258(03)00055-X","article-title":"The lipid and non-lipid effects of statins","volume":"99","author":"Wierzbicki","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.coph.2016.01.007_bib0025","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association's Muscle Safety Expert Panel: an assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.007_bib0035","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"The Diabetes Subpanel of the National Lipid Association Expert Panel: an assessment by the Statin Diabetes Safety Task Force: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0040","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"The National Lipid Association's Statin Safety Task Force: an assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0045","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"An assessment by the Statin Cognitive Safety Task Force: 2014 update","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MOL.0b013e3283613a55","article-title":"Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond","volume":"24","author":"Couture","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0060","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases","volume":"53","author":"Porez","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2016.01.007_sbref0065","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_sbref0070","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.007_bib0075","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jacl.2011.03.451","article-title":"Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Robinson","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_sbref0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.coph.2016.01.007_bib0085","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_bib0090","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/hmg\/ddr578","article-title":"Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification","volume":"21","author":"Tveten","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2016.01.007_bib0095","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacl.2015.01.001","article-title":"Understanding PCSK9 and anti-PCSK9 therapies","volume":"9","author":"McKenney","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_sbref0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coph.2016.01.007_bib0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coph.2016.01.007_bib0110","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.01.007_bib0115","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.atherosclerosis.2014.10.099","article-title":"ETC-1002: A future option for lipid disorders?","volume":"237","author":"Nikolic","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.coph.2016.01.007_bib0120","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coph.2016.01.007_sbref0125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 \u2013 executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_sbref0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia \u2013 full report","volume":"8","author":"Grundy","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.007_bib0140","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2014.04.009","article-title":"Curing atherosclerosis should be the next major cardiovascular prevention goal","volume":"63","author":"Robinson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.007_bib0145","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2016.01.007_bib0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2014.76","article-title":"The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future","volume":"96","author":"Hajhosseiny","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2016.01.007_bib0155","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2016.01.007_bib0160","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_bib0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_bib0170","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.atherosclerosis.2015.06.012","article-title":"Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature","volume":"242","author":"Ito","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.coph.2016.01.007_sbref0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"TG and HDL Working Group of the Exome Sequencing Project","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.coph.2016.01.007_sbref0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_bib0185","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_bib0190","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/cmdc.201402069","article-title":"Therapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltransferase (DGAT) inhibitors","volume":"9","author":"Naik","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.coph.2016.01.007_bib0195","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jacl.2012.04.034","article-title":"The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome","volume":"6","author":"Meyers","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.coph.2016.01.007_bib0200","series-title":"Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)","year":"2012"},{"key":"10.1016\/j.coph.2016.01.007_bib0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1194\/jlr.R039297","article-title":"Cardioprotective functions of HDLs","volume":"55","author":"Rye","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2016.01.007_bib0210","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.coph.2016.01.007_bib0215","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_bib0220","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.01.007_bib0225","series-title":"Lilly To Discontinue Development Of Evacetrapib For High-Risk Atherosclerotic Cardiovascular Disease","year":"2015"},{"key":"10.1016\/j.coph.2016.01.007_bib0230","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.01.007_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.01.008","article-title":"The effect of an apolipoprotein A-I-containing HDL-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia","volume":"169","author":"Hovingh","year":"2015","journal-title":"Am Heart J"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T17:25:20Z","timestamp":1536945920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489216300030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":47,"alternative-id":["S1471489216300030"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2016.01.007","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risk reduction: the future of cholesterol lowering drugs","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2016.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}